Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

NCT04279379 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Extranodal NK/T-cell Lymphoma

Interventions

DRUG: Sintilimab
DRUG: Decitabine

Sponsor

Beijing Tongren Hospital